AXTI · AXT Inc · Stock research

Current Thesis

The contested reclaim from 2026-08-04 resolved upward, and quickly. The Friday close sits just beneath the 2026-06-05 breakdown close of $89.04 and back above the 50-day moving average, $72.41 as of 2026-08-09, with the 200-day at $48.46.

The leg on offer is unchanged in substance: a customer-funded indium-phosphide capacity ramp one layer upstream of the 800G/1.6T optical interconnect build. What changed in the week of 2026-08-03 is the frame around it. On 2026-08-06 TrendForce carried Lumentum CEO Michael Hurlston describing the InP supply-demand gap as now wider than DRAM and NAND, with the shortfall above 30%. A single-company earnings beat on 2026-07-30 became an industry-level scarcity story six sessions later, and the bid widened accordingly.

Two of the three counterparties that signed capacity commitments report inside 72 hours of this note — Lumentum after the close 2026-08-11, Coherent after the close 2026-08-12. Both are the demand-side check on the ~$66M Q3 guide.

Bullish and bearish views on AXT Inc

The model's bull view on AXT Inc (AXTI), in brief: Q2 2026, reported 2026-07-30: revenue $47.6M against $34.1M consensus, versus $18.0M in Q2 2025 and $26.9M in Q1 2026. The bear view: Price has closed the gap to the consensus target. Both cases follow in full.

Bull Case

• Q2 2026, reported 2026-07-30: revenue $47.6M against $34.1M consensus, versus $18.0M in Q2 2025 and $26.9M in Q1 2026. GAAP gross margin 44.9% against 29.6% in Q1. Non-GAAP net income $11.9M, $0.19 per share, against $0.07 estimated. InP revenue $30.7M — the highest quarterly InP figure the company has recorded.
• Q3 2026 guide ~$66.0M versus a $38.8M Street figure, non-GAAP EPS $0.30–$0.32 against $0.11. On the 2026-07-30 call management said the number rests on export permits already granted or on product outside the restricted set, so the Chinese licensing variable that constrained Q4 2025 is pre-cleared for one quarter.
• Three committed agreements in seven weeks. Casela: Tongmei signed 2026-06-11 for a fixed CY2027 InP quantity at RMB 173,000,000 (~$25.4M). Coherent: three-year 6-inch InP master development and supply agreement effective 2026-06-25 with a $22.3M prepayment (8-K filed 2026-07-02). Lumentum: Capacity Reservation Agreement entered 2026-07-26 (8-K filed 2026-07-29) — initial deposit $43,500,000 due within 30 business days, a second $43,500,000 with terms set during CY2028, against a six-year minimum commitment.
• Backlog above $100M per the 2026-07-30 call, with a stated capacity path of ~$60M/quarter of InP exiting 2026 and ~$130M/quarter exiting 2027. Cash and investments $749M at 2026-06-30 against $123M at 2026-03-31; inventory $96.3M, up ~$6.2M in the quarter.
• Third-party corroboration of the constraint, 2026-08-06: the TrendForce piece attributes to Lumentum's CEO a supply gap exceeding memory's, the first sector-level datapoint on this bottleneck that does not originate with AXT management or its sell-side coverage.
• Sell-side reset 2026-07-30/31: five-analyst mean target $91.6 (3 Strong Buy / 2 Hold) — Northland $125, Wedbush $93, Needham $90 on an upgrade from Hold, B. Riley $55 Neutral with the target raised. BlackRock disclosed 4,653,059 shares, 7.1% of class, in a Schedule 13G filed 2026-07-27.

Bear Case

• Price has closed the gap to the consensus target. The $88.58 close on 2026-08-07 sits against a five-analyst mean of $91.6 struck on 2026-07-30/31, and above four of the five published targets other than Northland's $125. Further upside now requires target revisions rather than target convergence.
• The multiple re-rated with the price. P/S 45.04 and EV/sales 42.39 as of 2026-08-09, against 33.19 and 30.54 at the 2026-08-04 close, on a $5.65B market cap and $47.6M of quarterly revenue. Forward P/E 55.85.
• The prepayments are refundable liabilities. Coherent's $22.3M is refundable at Coherent's option if unused at expiry or termination; the Lumentum deposits are refundable on an uncured capacity failure, and the agreement is terminable if AXT misses its capacity commitment for more than six consecutive months.
• Corporate and insider supply has met strength twice. 8,560,311 shares priced at $64.25 in the April secondary; CEO Morris Young disclosed sales above $22M ahead of the 2026-06-05 breakdown from ~$89. Authorized common was raised from 70,000,000 to 120,000,000 shares effective 2026-06-04 against 63.82M outstanding.
• The short base has not been re-measured. 11.02M shares short, 18.27% of a 60.31M float, 1.11 days to cover — on a settlement date that predates the 2026-07-30 through 2026-08-07 sessions entirely. How much of the move off the 2026-08-03 low of $53.66 was covering is unknown until the report covering the 07-31 settlement lands.
• China concentration is unforecastable by management's own account. The 2026-07-30 call put China at 40–60% of revenue and stated that permit timing and approval beyond already-cleared product cannot be forecast.

Setup & Price Structure

Life-cycle: ACCELERATING, dated to 2026-08-06 and 2026-08-07. The 2026-08-06 TrendForce item moved the story from AXT's own print to a named third-party shortage claim, and 2026-08-07 traded +17.84% to $88.58 on 19.01M shares — volume expanding again after 13.51M and 11.22M on the two prior sessions. Fresh attention plus expanding participation is the accelerating signature, on top of a 2026-07-31 Needham upgrade to Buy and a 2026-07-31 B. Riley target raise. The counter-reading is that the label has a short half-life in this name: the same stock printed $143.16 in late May and $53.66 intraday on 2026-08-03.

Structure: the 2026-08-03 low of $53.66 and the $68.67 / $68.61 closes on 08-03 and 08-05 form the base of the current leg. The April secondary price of $64.25 now sits beneath that base rather than at it. Overhead, the 2026-06-05 close of $89.04 and the 2026-08-07 high of $89.49 mark the first shelf; the May peak at $143.16 is the outer reference.

Crowding and positioning observables: price closed $88.58 against a 50-day of $72.41 and a 200-day of $48.46; short interest of 11.02M shares was last measured on a settlement predating the whole move; single-stock leveraged ETFs tracking AXTI moved as much as 49% on 2026-07-31 against a 28.74% move in the shares, which concentrates mechanical rebalancing flow at the close; retail-facing coverage clustered heavily in the 2026-07-31 to 2026-08-07 window (multiple Benzinga movers items, a "$1,000 invested 15 years ago" piece on 2026-08-04). No earnings date is imminent — the print already happened on 2026-07-30 — so the near-term binaries belong to other companies' calls.

Catalyst Calendar (next 30 days)

• ~2026-08-10 (est.) — Q2 2026 Form 10-Q. First look at how the Casela and Coherent commitments are carried, customer-deposit and deferred-revenue balances, capex against the capacity plan, the composition of $96.3M of inventory, and the Tongmei redemption-right language. The Lumentum agreement is not included; the 8-K states it will be filed with the Q3 10-Q.
• 2026-08-11 — Lumentum FQ4 FY2026 results, after close. The counterparty on a six-year InP reservation reports sixteen days after entering it, and its CEO is the source of the 2026-08-06 shortage claim.
• ~2026-08-12 (est.) — FINRA short-interest report covering the 2026-07-31 settlement. First positioning read spanning the 07-30 and 07-31 gap sessions.
• 2026-08-12 — Coherent FQ4 FY2026 results for the quarter ended 2026-06-30, after close. The other prepaying customer; transceiver volume guidance reads directly onto the ~$66M Q3 figure.
• ~2026-08-26 (est.) — NVIDIA FQ2 FY2027 results. Sets the demand tone for the interconnect build the entire InP backlog is levered to.
• ~2026-09-04 (est.) — Lumentum initial $43,500,000 deposit falls due, 30 business days from the 2026-07-26 entry. Receipt converts a signed reservation into funded balance-sheet cash.

What Would Change Our Mind

The structure that matters is the base built between 2026-08-03 and 2026-08-05, not the highs. Giving back the entire three-session expansion leg — a weekly close below $68, losing the 2026-08-03 close of $68.67 and the 2026-08-05 close of $68.61 and returning price beneath the 50-day at $72.41 — would say the 2026-08-06 shortage headline bought three days of attention and no durable holders.

Second, the counterparty prints. Lumentum on 2026-08-11 or Coherent on 2026-08-12 guiding datacom below consensus, or declining to corroborate substrate tightness on the call, would break the third-party leg of the story while AXT's own guide stays intact for one more quarter.

Third, the funding proof. If the initial $43,500,000 Lumentum deposit has not landed by roughly 2026-09-04, that is the first slip in three agreements signed inside seven weeks, and the distance between a signed reservation and received cash becomes the whole argument.

Fourth, supply into strength. New Form 4 sales at post-run prices, or a shelf takedown or ATM disclosure in the Q2 10-Q despite $749M of cash and investments, would repeat the pattern set by the $64.25 April secondary and the June insider sales.

If instead coverage broadens to mainstream while price stalls under the 2026-08-07 high of $89.49 on falling volume, the correct label becomes SATURATED and the accelerating read is spent.

Correlation Notes

• Direct counterparties: LITE (reports 2026-08-11) and COHR (2026-08-12) are both customers and, in Lumentum's case, an InP producer in its own right — its capacity commentary cuts both ways for AXT.
• Demand tone: NVDA (~2026-08-26) sets the interconnect capex frame; optical module and transceiver names trade as the second derivative of the same order book.
• Mechanical flow: single-stock leveraged ETFs tracking AXTI amplified the 2026-07-31 move to as much as 49% against 28.74% in the underlying, which concentrates flow into the closing auction on trend days in either direction.
• Policy: Chinese export-permit policy on gallium and related materials is the shared risk factor across the compound-semiconductor substrate complex; management put China at 40–60% of revenue on 2026-07-30 and declined to forecast permit timing beyond already-cleared product.
• Analogue: the "worse than memory" framing attributed to Lumentum's CEO on 2026-08-06 links this narrative to the DRAM/NAND shortage trade, so memory-cycle sentiment now bleeds into how the InP story is priced.